Глиомы зрительного пути у детей. Обзор литературы. Часть II: лечение

Глиомы зрительного пути у детей. Обзор литературы. Часть II: лечение

Автор: Валиахметова Э.Ф., Холодов Б.В., Чулкова С.В., Егорова А.В., Горелышев С.К.

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Рубрика: Обзоры

Статья в выпуске: 1 т.18, 2018 года.

Бесплатный доступ

Глиомы зрительного пути (ГЗП) - это преимущественно доброкачественные опухоли. Несмотря на это, поведение ГЗП может быть агрессивным, что представляет серьезную угрозу для зрения, а иногда и для жизни, и усложняет тем самым лечение. Терапия ГЗП включает в себя динамическое наблюдение, хирургическое вмешательство, лекарственную 1 противоопухолевую и лучевую терапию (ЛТ). В статье представлен обзор современной литературы о значении всех методов лечения ГЗП с историческими аспектами, а также существующие и будущие тенденции в изменении лечения, в частности, таргетная терапия.

Глиомы зрительного пути, нейрохирургия, полихимиотерапия, лучевая терапия, таргетная терапия

Короткий адрес: https://sciup.org/14955567

IDR: 14955567

Список литературы Глиомы зрительного пути у детей. Обзор литературы. Часть II: лечение

  • Владимирова Л.Ю. МЕК как терапевтическая мишень в онкологии. Злокачественные опухоли. 2015. Т. 4. № 16. C. 20-27.
  • Горелышев С.К., Коновалов А.Н. Глиомы зрительных путей. Клиническая неврология. Под ред. А.С.Никифорова, А.Н.Коновалова, Е.И.Гусева. М.: Медицина. Основы нейрохирургии. 2004. Т. 2. № 1. С. 396-400.
  • Горелышев С.К., Матуев К.Б. Особенности нейрохирургических доступов у грудных детей с опухолями боковых и третьего желудочков. Нейрохирургия и неврология детского возраста. 2013. № 3 (37). C. 54-63.
  • Солтан П.С., Дубина М.В., Хачатрян В.А. Молекулярная генетика и лекарственная терапия глиальных опухолей мозга у детей. Нейрохирургия и неврология детского возраста. 2014. №3 (41). C. 60-67.
  • Abernethy L.J., Avula S., Hughes G.M., et al. Intra-operative 3-T MRI for paediatric brain tumours: Challenges and perspectives. Pediatr Radiol. 2012. V. 42. No. 2. P. 147-157.
  • Ahn Y., Cho B.K., Kim S.K., et al. Optic pathway glioma: outcome and prognostic factors in a surgical series. Childs Nerv Syst. 2006. V. 22. No. 9. P. 1136-1142.
  • Ater J.L., Zhou T., Holmes E., et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: A report from the Children’s Oncology Group. J Clin Oncol. 2012. V. 30. No. 21. P. 2641-2647.
  • Ater J.L., Xia С., Mazewski C.M., et al. Nonrandomized Comparison of Neurofibromatosis Type 1and Non -Neurofibromatosis Type 1 Children Who Received Carboplatin and Vincristine for Progressive Low-Grade Glioma: A Report From the Children’s Oncology Group. Cancer. 2016. V. 122. No. 12. P. 1928-1936.
  • Avery R.A., Hwang E.I., Jakacki R.I., Packer R.J. Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab. JAMA Ophthalmol. 2014. V. 132. No. 1. P. 111-114.
  • Banerjee A., Jakacki R.J., Onar-Thomas A., et al. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol. 2017. V. 19. No. 8. P. 1135-1144.
  • Bouffet E., Jakacki R.J., Goldman S., et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol. 2012. V. 30. No. 12. P. 1358-1363.
  • Bowers D.C., Mulne A.F., J. Reisch J.S., et al. Nonperioperative strokes in children with central nervous system tumors. Cancer. 2002. V. 94. No. 4. P. 1094-1101.
  • Bowers D.C., Liu Y., Leisenring W., et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2006. V. 24. No. 33. P. 5277-5282.
  • Chintagumpala M., Eckel S.P., Krailo M., et al. A pilot study using carboplatin, vincristine, and temozolomide in children with progressive/symptomatic low-grade glioma: A Children’s Oncology Group study. Neuro Oncol. 2015. V. 17. No. 8. P. 1132-1138.
  • Desai S.S., Paulino A.C., Mai W.Y., et al. Radiation-induced moyamoya syndrome. International Journal of Radiation Oncology Biology Physics. 2006. V. 65. No.4. P. 1222-1227.
  • Fouladi M., Wallace D., Langston J.W., et al. Survival and functional outcome of children with Hypothalamic/Chiasmatic tumors. Cancer. 2003. V. 97. No. 4. P. 1084-1092.
  • Fried I., Tabori U., Tihan T., et al. Optic pathway gliomas: A review. CNS Oncology. 2013. 16 V. 2. No. 2. P. 143-159.
  • Friedman H.S., Krischer J.P., Burger P., et al. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. J Clin Oncol. 1992. V. 10. No. 2. P. 249-256.
  • Fuss M., Hug E.B., Schaefer R.A., et al. Proton radiation therapy (PRT) for pediatric optic pathway gliomas: Comparison with 3D planned conventional photons and a standard photon technique. Int J Radiat Oncol Biol Phys. 1999. V. 45. No. 5. P. 1117-1126.
  • Gan H.W., Phipps K., Aquilina K., et al. Neuroendocrine morbidity after pediatric optic gliomas: A longitudinal analysis of 166 children over 30 years. J Clin Endocrinol and Metab. 2015. V. 100. No. 10. P. 3787-3799.
  • Gillett G.R., Symon L. Hypothalamic glioma. Surg Neurol. 1987. V. 28. No. 4. P. 291-300.
  • Gilmartin A.G., Bleam M.R., Groy A., et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res. 2011. V. 17. No. 5. P. 989-1000.
  • Gnekow A.K., Kortmann R.D., Pietsch T., Emser A. Low grade chiasmatic-hypothalamic glioma -Carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy: Report from the multicenter treatment study for children and adolescents with a low grade glioma -HIT-LGG 1996 -of the Society of Pediatric Oncology and Hematology (GPOH). Klin Padiatr. 2004. V. 216. No. 6. P. 331-342.
  • Gnekow A.K., Falkenstein F., Von Hornstein S., et al. Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. Neuro Oncol. 2012. V. 14. No. 10. P. 1265-1284.
  • Gnekow A.K., Walker D.A., Kandels D., et. al. A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (
  • Goodden J., Pizer B., Pettorini B., et al. The role of surgery in optic pathway/hypothalamic gliomas in children. J Neurosurg Pediatr. 2014. V. 13. No. 1. P. 1-12.
  • Greenberger B.A., Pulsifer M.B., Ebb D.H., et al. Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas. Intl J Radiat Oncol Biol Phys. 2014. V. 89. No. 5. P. 1060-1068.
  • Gururangan S., Cavazos C.M., Ashley D., et al. Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin Oncol. 2002. V. 20. No. 13. P. 2951-2958.
  • Gururangan S., Fisher M.J., Allen J.C., et al. Temozolomide in children with progressive low-17 grade glioma. Neuro Oncol. 2007. V. 9. No. 2. P. 161-168.
  • Hoffman H.J., Humphreys R.P., Drake J.M., et al. Optic pathway/hypothalamic gliomas: A dilemma in management. Pediatr Neurosurgy. 1993. V. 19. No. 4. P. 186-195.
  • Hug E.B., Muenter M.W., Archambeau J.O., et al. Conformal proton radiation therapy for pediatric low-grade astrocytomas. Strahlenther Onkol. 2002. V. 178. No. 1. P. 10-17.
  • Hutt-Cabezas M., Karajannis M.A., Zagzag D., et al. Activation of mtorc1/mtorc2 signaling in pediatric low-Grade glioma and pilocytic astrocytoma reveals mtor as a therapeutic target. Neuro Oncol. 2013. V. 15. No. 12. P. 1604-1614.
  • Hwang E.I., Jakacki R.I., Fisher M.J., et al. Long-Term Efficacy and Toxicity of Bevacizumab-Based Therapy in Children With Recurrent Low-Grade Gliomas. Pediatr Blood Cancer. 2013. V.60.No. 5. P. 776-782.
  • Janss A., Grundy R., Cnaan A., et al. Optic pathway and hypothalamic/chiasmatic gliomas in children younger than age 5 years with a 6-year follow-up. Cancer. 1995. V. 75. No. 4. P. 1051-1059.
  • Kelly J.P., Leary S., Khanna P., Weiss A.H. Longitudinal measures of visual function, tumor volume, and prediction of visual outcomes after treatment of optic pathway gliomas. Ophthalmology. 2012. V. 119. No. 6. P. 1231-1237.
  • Kieran M.W., Yao X., Macy M. et al. Final results of a prospective multi-institutional phase II study of everolimus (RAD001), an MTOR inhibitor, in pediatric patients with recurrent or progressive low-grade glioma. A POETIC consortium trial. Neuro Oncology. V. 16. Suppl 3:iii27.
  • Kieran M.W., Hargrave D.R., Cohen K.J., et al. Phase 1 study of dabrafenib in pediatric patients (pts) with relapsed or refractory BRAFV600E high-and low-grade gliomas (HGG, LGG), Langerhans cell histiocytosis (LCH), and other solid tumors (OST). J Clin Oncol. 2015. V. 33. Suppl. Abstr. 10004.
  • Laithier V., Grill J., Deley L., et al. Progression-Free Survival in Children With Optic Pathway Tumors: Dependence on Age and the Quality of the Response to Chemotherapy -Results of the First French Prospective Study for the French Society of Pediatric Oncology. J Clin Oncol. 2003. V.21.No. 24. P. 4572-4578.
  • Lassaletta A., Guerreiro Stucklin A., Ramaswamy V. et al. Profound clinical and radiological response to BRAF inhibition in a 2-month-old diencephalic child with hypothalamic/chiasmatic glioma. Pediatr Blood Cancer. 2016. V. 63. No. 11. P. 2038-2041.
  • Listernick R., Ferner R.E., Liu G.T., Gutmann D.H. Optic pathway gliomas in neurofibromatosis-1: Controversies and recommendations. Ann Neurol. 2007. V. 61. No. 3. P. 189-
  • Mahoney D.H., Cohen M.E., Friedman H.S,. et al. Carboplatin is effective therapy for young 18 children with progressive optic pathway tumors: A Pediatric Oncology Group phase II study. Neuro Oncol. 2000. V. 2. No. 4. P. 213-220.
  • Massimino M., Spreafico F., Riva D., et al. A lower-dose, lower-toxicity cisplatin-etoposide regimen for childhood progressive low-grade glioma. J Neurooncol. 2010. V. 100. No. 1. P. 65-71.
  • Massimino M., Spreafico F., Cefalo G., et al. High Response Rate to Cisplatin/Etoposide Regimen in Childhood Low-Grade Glioma. J Clin Oncol. 2002. V. 20. No. 20. P. 4209-4216.
  • McLaughlin M.E., Robson C.D., Kieran M.W., et al. Marked regression of metastatic pilocytic astrocytoma during treatment with imatinib mesylate (STI-571, Gleevec): a case report and laboratory investigation. J Pediatr Hematol Oncol. 2003. V. 25. No. 8. P. 644-648.
  • Merchant T.E., Kun L.E., Wu S., et al. Phase II trial of conformal radiation therapy for pediatric low-grade glioma. J Clin Oncol. 2009. V. 27. No. 22. P. 3598-3604.
  • Merchant T.E., Conklin H.M., Wu S., et al. Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: Prospective evaluation of cognitive, endocrine, and hearing deficits. JClin Oncol. 2009. V. 27. No. 22. P. 3691-3697.
  • Miller C., Guillaume D., Dusenbery K., et al. Report of effective trametinib therapy in 2 children with progressive hypothalamic optic pathway pilocytic astrocytoma: documentation of volumetric response. J Neurosurg Pediatr. 2017. V. 19. No. 3. P. 319-324.
  • Netson K.L., Conklin H.M., Wu S., et al. Longitudinal investigation of adaptive functioning following conformal irradiation for pediatric craniopharyngioma and low-grade glioma. Int J Radiat Oncol Biol Phys. 2013. V. 85. No. 5. P. 1301-1306.
  • Opocher E., Kremer L.C.M., Da Dalt L., et al. Prognostic factors for progression of childhood optic pathway glioma: A systematic review. Eur J Cancer. 2006. V. 42. No. 12. P. 1807-1816.
  • Packer R.J., Sutton L.N., Bilaniuk L.T., et al. Treatment of chiasmatic/hypothalamic gliomas of childhood with chemotherapy: an update. Ann Neurol. 1988. V. 23. No. 1. P. 79-85.
  • Packer R.J., Lange B., Ater J., et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol. 1993. V. 11. No. 5. P. 850-856.
  • Packer R.J., Ater J., Allen J., et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg. 1997. V. 86. No. 5. P. 747-754.
  • Packer R.J., Jakacki R.I., Horn M., et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer. 2009. V. 52. No. 7. P. 791-795.
  • Panizza B. Anatomico-Surgical Remarks on a Case of Medullary Fungus of the Eye. Editor P. Bizzoni. Pavia. Italya. 1821. P. 1-45.
  • Peyrl A., Azizi A., Czech T., et al. Tumor Stabilization Under Treatment With Imatinib in Progressive Hypothalamic-Chiasmatic Glioma. Pediatr Blood Cancer. 2009. V. 52. No. 4. P. 476-480.
  • Prados M., Edwards M.S., Rabbitt J., et al. Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neurooncol. 1997. V. 32. No. 3. P. 235-241.
  • Rosenstock J.G., Packer R.J., Bilaniuk L., et al. Chiasmatic optic glioma treated with chemotherapy. A preliminary report. J Neurosurg. 1985. V. 63. No. 6. P. 862-866.
  • Rosenstock J.G., Evans A.E., Schut L. Response to vincristine of recurrent brain tumors in children. J Neurosurg. 1976. V. 45. No. 2. P. 135-140.
  • Roth J.J., Santi M., Pollock A.N., et al. Chromosome band 7q34 deletions resulting in KIAA1549-BRAF and FAM131B-BRAF fusions in pediatric low-grade gliomas. Brain Pathol. 2015. V. 25. No. 2. P. 182-192.
  • Rutka J.T., Kuo J.S. Pediatric surgical neuro-oncology: Current best care practices and strategies. J Neurooncol. 2004. V. 69. No. 1-3. P. 139-150.
  • Sawamura Y., Kamada K., Kamoshima Y., et al. Role of surgery for optic pathway/hypothalamic astrocytomas in children. J Neurooncol. 2008. V. 10. No. 5. P. 725-733.
  • Shofty B., Weizman L., Joskowicz L., et al. MRI internal segmentation of optic pathway gliomas: Clinical implementation of a novel algorithm. Child Nerv Syst. 2011. V. 27. No. 8. P. 1265-1272.
  • Skrypek M., Foreman N., Guillaume D., Moertel C. Pilomyxoid Astrocytoma Treated Successfully With Vemurafenib. Pediatr Blood Cancer. 2014. V. 61. No. 11. P. 2099-2100.
  • Steinbok P., Hentschel S., Almqvist A., et al. Management of optic chiasmatic/hypothalamic astrocytomas in children. J Neurol Sci. 2002. V. 29. No. 2. P. 132-138.
  • Sutton L.N., Molloy P.T., Sernyak H., et al. Long-term outcome of hypothalamic/chiasmatic astrocytomas in children treated with conservative surgery. J Neurosurg. 1995. V. 83. No. 4. P. 583-589.
  • Tsang D.S., Murphy E.S., Merchant T.E. Radiation Therapy for Optic Pathway and Hypothalamic Low-Grade Gliomas in Children. Int J Radiat Oncol Biol Phys. 2017. V. 99. No. 3. P. 642-651.
  • Ullrich N.J., Robertson R., Kinnamon D.D., et al. Moyamoya following cranial irradiation for primary brain tumors in children. Neurology. 2007. V. 68. No. 12. P. 932-938.
  • Valdueza J.M., Lohmann F., Dammann O., et al. Analysis of 20 primarily surgically treated chiasmatic/hypothalamic pilocytic astrocytomas. Acta Neurochir (Wien). 1994. V. 126. No. 1. P. 44-50.
  • Willard V.W., Conklin H.M., Wu S., et al. Prospective longitudinal evaluation of emotional and behavioral functioning in pediatric patients with low-grade glioma treated with conformal radiation 20 therapy. J Neurooncology. 2015. V. 122. No. 1. P. 161-168.
  • Wisoff J.H., Abbott R., Epstein F. Surgical management of exophytic chiasmatic-hypothalamic tumors of childhood. J Neurosurg. 1990. V. 73. No. 5. P. 661-667.
  • Yalon M., Rood B., MacDonald T., et al. A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG). Pediatr Blood Cancer. 2013. V. 60. P. 71-76.
Еще
Статья научная
SciUp 2024 © 2024 ©